Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Julie Kanter, MD
Researcher Associate Professor
Division of Hematology & Oncology
University of Alabama School of Medicine
1720 2nd Avenue South, NP 2540
Birmingham, Alabama, United States
Dr. Julie Kanter is the Associate Professor of hematology and oncology and Director of the Comprehensive Sickle Cell Center at the University of Alabama at Birmingham. Her academic focus is on improving the comprehensive care of persons with sickle cell disease throughout the lifespan and clinical and translational research to better understand and address issues in treatment and prevention in sickle cell disease.
Prior to moving to Alabama, Dr. Kanter was the Director of sickle cell disease research and Associate Professor of Pediatrics at the Medical University of South Carolina. Dr. Kanter is very committed to improving outcomes in sickle cell disease and ensuring those outcomes reach the affected individuals. She works closely with national partners including the American Society of Hematology and the NIH on both advocacy and research.
Board Certification:
– Pediatrics: Pediatric Hematology-Oncology
Specialties:
– Pediatric Hematology/Oncology
– Cancer
– Pediatric
Representative Publications:
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events
+myBinderRelated Content
-
Kathryn Hassell, MDDr. Hassell provides inpatient and outpa...
-
Improving Quality of Care for Sickle Cell Patients in the Pediatric Emergency DepartmentOBJECTIVE: The aim of this study was to ...
-
John T. Horan MD, MPHJohn T. Horan, MD, MPH, is Associate Pro...
-
A novel approach to reducing admissions for children with sickle cell disease in pain crisis through individualizati...BACKGROUND:Vaso-occlusive crisis (VOC) i...
-
Toronto Neuroscientist Getting Closer to Tailored Treatments for Chronic PainDaily tasks most people don't think too ...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
-
Foundation For Sickle Cell Disease ResearchThe Foundation for Sickle Cell Disease R...
